Literature DB >> 9434204

Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice.

A Chakrabarti1, J E Ekuta, E S Onaivi.   

Abstract

The objective of the present study was to determine the neurobehavioral effects of the putative endogenous cannabinoid ligand, anandamide, and its influence on cannabinoid (CB1) receptor gene expression. The effect of acute administration of anandamide to C57BL/6, DBA/2, and ICR mice were evaluated in motor function and emotionality tests. The C57BL/6 and ICR mouse strains were more sensitive than the DBA/2 strain to the depression of locomotor activity and stereotyped behavior caused by anandamide. Although anandamide produced catalepsy in all three strains, anandamide induced ataxia in the minus-maze test only in the C57BL/6 animals and only at the lowest dose used. In the plus-maze test system, anandamide produced a mild aversive response, and by the third day of treatment the mouse strains developed an intense aversion to the open arms of the plus-maze. Northern analysis data using the recently cloned mouse cannabinoid receptor cDNA as a probe indicated that there was abundant expression of CB1 gene in the whole brain of the ICR mouse than in the brains of the C57BL/6 and DBA/2 strains with or without pretreatment with anandamide. The anandamide induced neurobehavioral profile does not seem to correspond to the CB1 gene expression in the mouse strains. It is, therefore, unlikely that the CB1 receptor mediates all the cannabinomimetic effects of anandamide in the brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9434204     DOI: 10.1016/s0361-9230(97)00291-8

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  9 in total

1.  The effects of acute treatment with delta9-THC on exploratory behaviour and memory in the rat.

Authors:  R Hernández-Tristán; C Arévalo; S Canals; M L Leret
Journal:  J Physiol Biochem       Date:  2000-03       Impact factor: 4.158

2.  In-vitro and in-vivo action of cannabinoids.

Authors:  B E Akinshola; A Chakrabarti; E S Onaivi
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

3.  The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.

Authors:  F Maingret; A J Patel; M Lazdunski; E Honoré
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

4.  In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.

Authors:  Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  Pharmacol Biochem Behav       Date:  2020-04-02       Impact factor: 3.533

5.  Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison.

Authors:  Justine Renard; Marie-Odile Krebs; Thérèse M Jay; Gwenaëlle Le Pen
Journal:  Psychopharmacology (Berl)       Date:  2012-09-16       Impact factor: 4.530

6.  Long-term CB₁ receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.

Authors:  Simone Tambaro; Maria Lauda Tomasi; Marco Bortolato
Journal:  Neuropharmacology       Date:  2013-02-24       Impact factor: 5.250

7.  The Influence of Anandamide on the Anterior Pituitary Hormone Secretion in Ewes-Ex Vivo Study.

Authors:  Dorota Tomaszewska-Zaremba; Karolina Wojtulewicz; Kamila Paczesna; Monika Tomczyk; Katarzyna Biernacka; Joanna Bochenek; Andrzej Przemysław Herman
Journal:  Animals (Basel)       Date:  2020-04-17       Impact factor: 2.752

8.  Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide.

Authors:  E L Veale; R Buswell; C E Clarke; A Mathie
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Antiaversive effects of cannabinoids: is the periaqueductal gray involved?

Authors:  F A Moreira; D C Aguiar; A C Campos; S F Lisboa; A L Terzian; L B Resstel; F S Guimarães
Journal:  Neural Plast       Date:  2008-12-02       Impact factor: 3.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.